Connect with us

CBD News

Senator Chuck Schumer Calls for Decriminalization In Response to Cannabis Banking Bill

Published

on

Senator Chuck Schumer Calls for Decriminalization In Response to Cannabis Banking Bill
  • Chuck Schumer believes that the cannabis banking bill could stop progress on the reform of cannabis prohibition.
  • An expedited process may be used by the Senate to delay a vote on the cannabis banking bill.

The cannabis industry in the United States has been rich with difficulties throughout its time, and one of the big issues has been the lack of banking opportunities in this sector. As cannabis is federally illegal, most banks will not offer banking services, leaving dispensaries and other state-legalized businesses to accept cash only or seek out alternative payment options. While there is a cannabis banking bill being reviewed that could help with this one concern, Sen. Chuck Schumer believes that there is still so much more that the federal government could and should do.

On Thursday, Schumer posted a tweet that called for “decriminalization at the federal level,” as well as reformation of the criminal justice system and new opportunities for small businesses owned by minorities and women. In fact, he goes as far as to say that Congress shouldn’t simply enact the new bill and “think the job is done.”

Schumer added that there are many civil rights groups that want the planned vote on the financial services legislation to be held off. The organizations, which include the ACLU, Human Rights Watch, and Drug Policy Alliance (among others), are worried that the passing of the banking bill will push broader legislation efforts aside that would otherwise be focused on ending the federal prohibition on marijuana.

Schumer’s post, which he had quoted Marijuana Moment in, mentioned Rep. Alexandria Ocasio-Cortez. This Thursday, she had commented that she shares the groups’ concerns.

To be clear, Schumer didn’t say directly that the banking vote should be entirely called off before the broader reform happens. Instead, he noted that the job is far from over, and that he agreed with groups that are hoping for delays. However, House Majority Leader Steny Hoyer already announced intentions to bring the legislation to the floor before this month is over, and leaders plan to use a suspension of the rules to expedite the process. This process only requires 290 votes, or two-thirds majority, to pass.

At this point, the legislation has 206 cosponsors signed on, and the chief sponsor of the Secure and Fair Enforcement (SAFE) Banking Act – Ed Perlmutter – has already moved for changes to the legislation. Ultimately, the amendments would likely bring in more GOP votes. The series of changes would include banking protections for hemp and CBD companies, as well as preventing the regulators in the financial industry from targeting certain industries as being at a higher risk for fraud, which could sway Republicans. Still, for the most part, this legislation has been fairly bipartisan.

At the Senate, the bill will likely see a much tougher road. Majority leader Mitch McConnell has already supported the enactment of hemp legalization last year. However, he calls marijuana the “illicit cousin” of the crop, so it won’t likely see any of his support. Mike Crapo, the Senate Banking Committee Chairman, took a surprising approach, stating this month that he was planning on a vote for the cannabis banking legislation in his panel, hoping to make this happen before the end of the year.

Rep. Maxine Waters, who is the chair of the House Financial Services Committee, stated that she understands the concerns that advocacy groups have about this baking vote. However, the legalization bill by Judiciary Chairman Jerrold Nadler has been stuck without advancing, which means that the Democrats in the House are essentially tied. Waters commented, “[W]hat’s going to happen is Mr. Perlmutter’s bill that gives safe harbor to the banks is going to move, and whenever Judiciary gets that bill done, then it’s going to move too with the same kind of support that Mr. Perlmutter’s bill is going to get.”

One of the groups that signed the letter for stopping the banking vote, the Leadership Conference on Civil and Human Rights, expressed gratitude over the comments from Schumer. The group added that broader reform legislation should be considered in an effort to “address marijuana prohibition holistically and inclusively.”

A separate bill was filed by Schumer in May, aiming to deschedule cannabis entirely, while eliciting participation in the industry from communities that have been the victim of the effects of prohibition.

Denis is one of the most experienced researchers for reviews we have with years of experience in writing about CBD products. He will be one of the most viewed authors due to his own thrill in sharing what he is learning about cannabidiol and supplement use. With a goal of providing clarity within the budding CBD oil industry, Denis will be spending much of the year going through a catalogue of cannabis oil companies in the near future.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.